Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 10, Issue 7, Pages 823-830Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2014.918847
Keywords
anti-TNF- antibodies; golimumab; rheumatoid arthritis treatment; safety of TNF- inhibition; TNF- inhibition
Categories
Funding
- Abbott Laboratories
- Amgen
- AstraZeneca Pharmaceuticals
- Bristol-Meyers Squibb
- F. Hoffman LaRoche
- Genentech
- Janssen
- Johnson and Johnson
- Merck/Schering Plough
- Novartis
- Pfizer
- UCB
- Wyeth
Ask authors/readers for more resources
Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists' armamentarium and to appreciate more fully its long-term safety.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available